ArticleHealth affairs scholar2026
Effect of an out-of-pocket insulin cap in Medicare part D.
Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Out-of-pocket (OOP) costs can often impede patients' access to prescription drugs. The Inflation Reduction Act of 2022 (IRA) limited OOP costs for insulin products covered by the Medicare Part B and Part D programs to no more than $35 for a one-month supply. Methods: This analysis uses prescription drug data from Medicare Part D and commercially insured patients along with a difference-in-differences specification to estimate changes in OOP costs among Medicare Part D enrollees after policy implementation. Results: We estimate that the Part D enrollees most likely to be affected by the policy saw a $34.71 reduction in average OOP costs per prescription across all insulins compared to what might have occurred absent the policy in 2023. Conclusion: These findings suggest that targeted limits on OOP costs for high-value drugs can reduce the cost burden for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.